Benzinga | Sep 30, 2021 08:07AM EDT

Mersana Therapeutics To Announce Target And Present New Preclinical Data For XMT-2056 At The AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Details of the presentation are as follows:

Plenary Session Title: Tumor-Targeted Conjugates: A Growing Family

Presentation Title: XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate

Date/Time: Thursday, October 7, 2021 from 12:50 -- 2:40 p.m. ET

Presenter: Timothy B. Lowinger, Ph.D., Chief Science & Technology Officer, Mersana Therapeutics

A replay of the webcasted presentation will be available on October 7th after 4 p.m. ET on the Investors & Media section of the Mersana website at www.mersana.com.